Could a triple therapy help rectal cancer patients avoid a colostomy bag?
NCT ID NCT07397442
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tests a new combination of short-course radiation, two immunotherapy drugs (Qibei'an and Camrelizumab), and chemotherapy (XELOX) in 19 people with locally advanced rectal cancer. The goal is to see if this approach can make the tumor disappear completely, allowing patients to avoid permanent colostomy. All participants receive the experimental treatment, and they will be followed for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Short-course radiotherapy, Qibei'an (iparolizumab-tovorilimab), Camrelizumab, and XELOX chemotherapy (oxaliplatin + capecitabine)
What this could lead to
If successful, this combination could help more people with rectal cancer avoid permanent colostomy bags by making the tumor disappear completely before surgery.
What could go wrong
This is a very early, small study with only 19 people, so results may not apply to everyone. The combination of radiation, chemo, and immunotherapy may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••